These results demonstrated that ZNF304/miR-183-5p/FOXO4 axis played essential role in promoting ccRCC progression, which suggests that disruption of this axis may be a potential therapeutic target in ccRCC. This evidence concerns the gene ZNF304 and nonpapillary renal cell carcinoma.